Sign in Subscribe
Cancer research

Bezlotoxumab Shows Promise in Pediatric Stem Cell Transplant Patients with Recurrent Clostridioides Difficile Infection

Strategic Insights

— 1 min read

Researchers at the University of Texas MD Anderson Cancer Center have published a new report on the use of bezlotoxumab, a monoclonal antibody, in treating recurrent clostridioides difficile (CDI) infection in pediatric stem cell transplant (SCT) patients. The study found that bezlotoxumab, when used in conjunction with antibiotic therapy, was effective in treating recurrent CDI without increasing adverse events. The study also noted that bezlotoxumab did not impact the management of graft-versus-host disease in pediatric SCT patients. This new research provides valuable insights into the safety and efficacy of bezlotoxumab in pediatric SCT patients.

Key Takeaways:

  • Bezlotoxumab, a monoclonal antibody, has shown efficacy in treating recurrent CDI in adult populations, but its safety and efficacy in pediatric SCT patients were unknown prior to this study.
  • The study involved a multi-institutional experience with pediatric SCT patients treated with bezlotoxumab for recurrent CDI.
  • The researchers found that bezlotoxumab was not associated with increased adverse events in pediatric SCT patients.
  • Bezlotoxumab did not impact the management of graft-versus-host disease in pediatric SCT patients.
  • The study concluded that bezlotoxumab is safe to use in pediatric patients in the peri-transplantation period.
  • The researchers highlighted the need for further research on the use of bezlotoxumab in pediatric SCT patients.
  • The study had a total of 15 pediatric SCT patients with recurrent CDI who were treated with bezlotoxumab.
  • The average age of the patients was 11.7 years, and the median time since SCT was 55 days at the time of bezlotoxumab administration.
  • The incidence of adverse events was not significantly different between the bezlotoxumab group and the antibiotic-only group.

Statistics:

  • The study involved 15 pediatric SCT patients with recurrent CDI who were treated with bezlotoxumab.
  • The average age of the patients was 11.7 years.
  • The median time since SCT was 55 days at the time of bezlotoxumab administration.
  • The incidence of adverse events was not significantly different between the bezlotoxumab group (73.3%) and the antibiotic-only group (66.7%).
  • The most common adverse events reported in the study included fever, rash, and gastrointestinal disturbances.

Sources:

  • NewsRx. Studies from University of Texas MD Anderson Cancer Center Provide New Data on Monoclonal Antibodies (Bezlotoxumab As Treatment for Recurrent/chronic clostridioides Difficile Infection In Pediatric Stem Cell Transplant Recipients: a ...). Immunotherapy Weekly. August 6, 2025; p 594.
  • Bezlotoxumab As Treatment for Recurrent/chronic clostridioides Difficile Infection In Pediatric Stem Cell Transplant Recipients: a Multi-institutional Experience. Pediatric Blood & Cancer, 2025.

Read more